2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, Research, AML, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult
PAPER

3410 Venetoclax combined with decitabine/azacitidine and aclarubicin (VAA) in relapsed/refractory acute myeloid leukemia: A prospective, multicenter, phase II trial

Qian Sun, MD, Hongrui Zhang, MD2, Wenjie Liu, MD3, Yu Zhu, MD4, Sixuan Qian5, Jianyong Li, MD6, Lei Fan, MD7, Ming Hong, MD8
1 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province, China
2 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province, China
3 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province, China
4 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province, China
5 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province, China
6 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province, China
7 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province, China
8 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province, China

Background: Patients with relapsed/refractory acute myeloid leukemia (R/R AML) have a dismal prognosis; salvage chemotherapy yields complete remission (CR) rates of 20%-40%, and median overall survival (OS) is often <6 months. Aclarubicin exerts antileukemic activity via chromatin damage with markedly lower cardiotoxicity than conventional anthracyclines. Combining aclarubicin with the BCL-2 inhibitor venetoclax and a hypomethylating agent (HMA) may enhance efficacy while reducing toxicity. This study evaluated the efficacy and safety of venetoclax plus decitabine/azacitidine and aclarubicin (VAA) in R/R AML.

 

Methods: This prospective, multicenter, single-arm phase II trial (ChiCTR2400088404) planned to enroll 28 patients; 27 were actually enrolled (WHO 2016 R/R AML, age≥18 years, ECOG 0-2). The VAA regimen: venetoclax 100 mg d1, 200 mg d2, 400 mg d3-21 orally; decitabine 20 mg/m2/d d1-5 or azacitidine 75 mg/m2/d d1-7 (per patient preference); aclarubicin 10 mg/m2/d d1-4. Response was assessed after one cycle. Patients achieving composite CR (CRc=CR+CRi) proceeded to allo-HSCT if a donor was available; others continued VAA or cytarabine-based consolidation, followed by mutation-targeted maintenance. The primary endpoint was CRc rate after one cycle. Secondary endpoints: partial response (PR) rate, overall response rate (ORR), measurable residual disease (MRD) negativity, OS, disease-free survival (DFS), and adverse events (AEs).

 

Results: Median age was 56 (18-75) years; 19 (70.4%) were male; 16 (59.3%) had refractory disease. ELN 2022 risk: favorable 2 (7.4%), intermediate 5 (18.5%), adverse 20 (74.1%). KMT2A rearrangements were present in 2, FLT3-ITD in 6 (22.2%), TP53 mutations in 6 (22.2%). After one cycle, CRc rate was 51.9% (14/27), PR rate 14.8%, ORR 66.7%. Among CRc patients, 71.4% (10/14) achieved MRD negativity. With a median follow-up of 13.3 months, median OS was 4.9 months; 6-month, 1-year, and 2-year OS rates were 42.8%, 33.3%, and 33.3%. Median DFS was 6.1 months, with 6-month, 1-year, and 2-year DFS rates of 50.4%, 42.0%, and 42.0%. Grade ≥3 AEs were predominantly hematologic: neutropenia 81.5%, anemia 70.4%, thrombocytopenia 85.2%, febrile neutropenia 48.1%, pneumonia 29.6%. Non-hematologic toxicities were mild.

 

Conclusions: In this heavily adverse-risk R/R AML cohort (74.1% adverse-risk, 22.2% TP53-mutated), the VAA regimen produced a CRc rate of 51.9%, MRD negativity of 71.4%, and durable 1-/2-year OS of 33.3%. Adding aclarubicin to the venetoclax-HMA backbone exploits its unique chromatin-damaging mechanism (nucleosome disassembly and histone eviction independent of DNA double-strand breaks) with minimal cardiotoxicity and secondary malignancy risk, favoring elderly or cardiac-compromised patients. Grade 3-4 cytopenias were common but manageable, and the regimen effectively bridged to allo-HSCT, offering long-term survival potential. Limitations include the single-arm design, small sample size, and limited follow-up; randomized studies are warranted. VAA is an effective, low-toxicity salvage strategy for R/R AML with promising clinical applicability.

 

Wenjie Liu, MD: No relevant conflicts of interest to declare.